Thursday, August 25, 2011 4:39:51 PM
FDA Approves Shire's Treatment For Swelling Disorder
11:14a ET August 25, 2011 (Dow Jones)
FDA Approves Shire's Treatment For Swelling Disorder
DOW JONES NEWSWIRES
Shire PLC's (SHPGY, SHP.LN) treatment for a rare swelling disorder was approved by the U.S. Food and Drug Administration.
The drug, Firazyr, is the third drug approved in the U.S. to treat attacks of a rare condition called hereditary angioedema, according to the FDA.
Firazyr is the first on-demand treatment for hereditary agiodema that patients can inject themselves when they feel an attack coming on, instead of seeking a health-care professional. This rare disorder is a potentially fatal condition that causes severe swelling in the hands and feet, gastrointestinal tract and upper airway.
The other FDA approved treatments are CSL Behring's Berinert to treat facial and abdominal attacks of the condition, and Dyax Corp.'s (DYAX) Kalbitor to treat acute attacks in patients ages 16 years and older.
-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM